Osteoporosis is more common after menopause. Approximately
two million osteoporotic fractures occur annually in the United States, which
create physical and psychological burdens for affected women by
diminishing their independence and quality of life.
A recent analysis of results from a randomized controlled clinical trial indicates that Abaloparatide-SC, a novel therapy for osteoporosis, provides consistent protection against bone fractures in postmenopausal women with osteoporosis regardless of their baseline bone density, age, and previous history of fracture.
Investigators in the ACTIVE trial previously found that that the drug reduces fractures and increases bone mineral density in postmenopausal women with osteoporosis. This latest analysis, which is published in the Journal of Bone and Mineral Research (published by the American Society for Bone and Mineral Research), evaluated whether these benefits were consistent across different levels of baseline risk.